| Alaska Regional Medical Group, Llc | |
|
2841 Debarr Rd Anchorage AK 99508-2958 | |
| (907) 433-5100 | |
| (907) 433-5110 |
| Full Name | Alaska Regional Medical Group, Llc |
|---|---|
| Speciality | Family Medicine |
| Location | 2841 Debarr Rd, Anchorage, Alaska |
| Authorized Official Name and Position | Louis Joseph (VP) |
| Authorized Official Contact | 6153737630 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Alaska Regional Medical Group, Llc 2000 Health Park Dr Brentwood TN 37027-4525 Ph: (615) 373-7600 | Alaska Regional Medical Group, Llc 2841 Debarr Rd Anchorage AK 99508-2958 Ph: (907) 433-5100 |
| NPI Number | 1619370319 |
|---|---|
| Provider Enumeration Date | 10/08/2014 |
| Last Update Date | 01/02/2023 |
| Medicare PECOS PAC ID | 6507181948 |
|---|---|
| Medicare Enrollment ID | O20150206000717 |
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619370319 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Kathleen E Young |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326010232 PECOS PAC ID: 7012004013 Enrollment ID: I20071107000157 |
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
| Provider Name | Rachel Arnold |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689034241 PECOS PAC ID: 4789976069 Enrollment ID: I20160706002243 |
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
| Provider Name | Francisco B Rodriguez |
|---|---|
| Provider Type | Practitioner - Cardiac Surgery |
| Provider Identifiers | NPI Number: 1063434504 PECOS PAC ID: 3678543394 Enrollment ID: I20211006001250 |
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
| Provider Name | Richard Joseph Leone |
|---|---|
| Provider Type | Practitioner - Cardiac Surgery |
| Provider Identifiers | NPI Number: 1821058850 PECOS PAC ID: 1254322142 Enrollment ID: I20230126001742 |
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
| Provider Name | Gilbert Reynolds Schorlemmer |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1629060553 PECOS PAC ID: 6103814736 Enrollment ID: I20231010003006 |
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
| Provider Name | John Charles Dugal |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1851482665 PECOS PAC ID: 9739204702 Enrollment ID: I20231121003156 |
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
News Archive
Experts at the Keck School of Medicine of the University of Southern California and the USC School of Pharmacy are available to discuss critical national healthcare and healthcare policy issues.
Intensivists caution against the use of premature novel therapies in lieu of traditional critical care principles in patients with COVID-19 in a recent correspondence letter in the American Journal of Respiratory Cell and Molecular Biology.
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.
› Verified 6 days ago
Alaska Premier Health Alaska Sports Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3300 Arctic Blvd, 101, Anchorage, AK 99503 Phone: 907-561-3488 Fax: 907-562-3488 | |
Alaska Family Care Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4001 Dale Street, Suite 210, Anchorage, AK 99508 Phone: 907-929-5888 Fax: 907-929-5882 | |
Daryl M. Mcclendon, M.d., P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3851 Piper St, Suite U466, Anchorage, AK 99508 Phone: 907-569-1333 Fax: 907-569-1433 | |
Willow Wellness Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3030 Wendys Way Unit A, Anchorage, AK 99517 Phone: 406-253-7924 | |
Douglas Carter Smith, Md Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 17741 Mountainside Village Dr, Anchorage, AK 99516 Phone: 907-345-0728 Fax: 907-345-0728 | |
Internal Medicine Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2841 Debarr Rd Ste 50, Anchorage, AK 99508 Phone: 907-276-2811 Fax: 907-276-2810 | |
Summit Family Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2741 Debarr Rd, Suite C308, Anchorage, AK 99508 Phone: 907-272-3366 Fax: 907-272-0269 |